Article
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
Cancer science - 1 May 2013
Furuyama Kazuto, Harada Taishi, Iwama Eiji, Shiraishi Yoshimasa, Okamura Kyoko, Ijichi Kayo, Fujii Akiko, Ota Keiichi, Wang Shuo, Li Heyan, Takayama Koichi, Giaccone Giuseppe, Nakanishi Yoichi
Abstract excerpt
The presence of epidermal growth factor receptor (EGFR) somatic mutations in non-small-cell lung cancer patients is associated with response to treatment with EGFR-tyrosine kinase inhibitors, such as gefitinib and erlotinib. More than 100 mutations in the kinase domain of EGFR have been identifie...
Topics
- Afatinib
- Antineoplastic Agents
- Breast Neoplasms
- Cell Line, Tumor
- ErbB Receptors
- Erlotinib Hydrochloride
- Exons
- Gefitinib
- Humans
- MCF-7 Cells
- Mutation
- Phosphorylation
- Protein Kinase Inhibitors
- Protein Structure, Tertiary